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Abstract 
Food allergy appears to have its roots in an insufficient exposure to a diverse range of environmental microbiota 
during early life. Microbial exposure ensures the colonization of the gastrointestinal tract with commensal microbes, 
which is necessary for the induction of a balanced and tolerogenic immune function. High-throughput sequencing 
technology has facilitated in-depth studies of the gut microbiota as well as bacterial-derived metabolites. Although 
the role of the microbiota in allergies is now widely studied, its importance for food allergy was only recently noted. 
Studies in human cohorts have shown that there is an association of dysbiosis and pathogenesis of food allergy, while 
studies from animal models have demonstrated the capacity of specific species in the gut microbiota to alter immune 
response, which may lead to the desensitization of food allergy. This article reviews the role of the gut microbiota in 
food allergy, and discusses the influence of environmental factors as well as prevention and management strategies 
relating to such regulatory mechanism.
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Introduction
For decades, many cultivated microorganisms have been 
discovered by the microbiological culture technique, but 
these represent only a minority of the microbial species 
of the gut. The use of next generation high-through-
put sequencing techniques has widened tremendously 
our knowledge of the human microbiota composition 
and its relationship to disease. The human body is esti-
mated to consist of 10–100  trillion microbes, and more 
than 1000 bacterial species [1]. The highest number of 
microbes are found in the human gut [2]. The number 
of microbes found in the human gut are 10 times the 
number of cells making up the human body [3], although 
this ratio has been disputed [4]. Studies in the past few 
years have identified a critical role of the gut microbiota 
in shaping the immune system [5–8]. The gut microbi-
ota is involved in the development of the organs of the 
immune system, and determines the tendencies of host 
immune responses. Research on the association between 
immune diseases and gut microbiota has reported that 
alterations in commensal bacteria can induce changes to 
the immune system [2, 9] which affect regulation of host 
metabolism, immune system maturation, and develop-
ment of oral tolerance [10]. Thus, attempts to mitigate 
allergic diseases through adjusting the diversity and indi-
viduality of the gut microbiota have increased.
This review article outlines recent insights into the role 
of the gut microbiota in food allergy, the influence of 
environmental factors as well as prevention and manage-
ment strategies involving the gut microbiota.
Dysbiosis and food allergy
Dysbiosis refers to a change in the microbiota com-
position and function such that it disrupts gut home-
ostasis and contributes to diseases [11]. There are 
increasing evidence from human studies suggesting 
that dysbiosis is associated with pathogenesis of food 
allergy (Table  1) [12–23]. Although these studies are 
not able to identify specific bacterial taxa that are 
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consistently associated with food allergy due to het-
erogeneity in study design, such as different sampling 
time points, different techniques used to characterize 
the gut microbiota, and different allergic phenotypes, 
these studies show microbiota diversity and composi-
tion are significantly associated with the onset of food 
allergy.
Until now, it remains unclear how dysbiosis exactly 
affects the immune system in the development of 
food allergy but studies suggest that the gut micro-
biota influences the immune system by affecting host 
metabolism [2, 24–26] and the alteration of adaptive 
immunity [27, 28].
Metabolic and immune effects
Major attention has been directed to the possible role of 
short-chain fatty acids, such as butyrate, propionate, and 
acetate in affecting the immune system (Table 2) [29–32], 
since short-chain fatty acids are the main product of the 
digestive action of the gut microbiota [29, 30]. Produc-
tion of short-chain fatty acids, particularly butyrate, is 
able to enhance the Vitamin A metabolism, in turns 
inducing the activity of ALDH in CD103+MLN DCs, 
and increasing the percentages of T regulatory (Tregs) 
cells and increasing IgA production [33]. Meanwhile, 
short-chain fatty acids are able to inhibit histone deacety-
lases activity, resulting in regulation of aldh1a1 expres-
sion, which contributes to immune tolerance. Other than 
this, short-chain fatty acids can bind metabolite-sensing 
G-protein coupled receptors, GPR43 or GPR109A [34], 
Table 1 Main gut microbiota differences between patients with and without food allergy
Study Types of food allergy Association with food allergy References
Bunyavanich et al. Cow’s milk ↓Clostridia, Firmicutes [12]
Savage et al. Cow’s milk, egg, wheat, soy, nuts ↓Citrobacter, Oscillospira, Lactococcus, Dorea [14]
Azad et al. Cow’s milk, egg, peanut ↑Enterobacteriaceae
↓Bacteroidaceae
[15]
Hua et al. Peanut ↓Clostridiales
↑Bacteroidales
[16]
Inoue et al. Egg, wheat, soybean, sesame, cow’s milk, peanut, shrimp, 
crab
↓Dorea, Akkermansia
↑Veillonella
[17]
Ling et al. Cow’s milk, egg, wheat, nut, peanuts, fish, shrimp, soy beans ↓Bacteroidetes, Proteobacteria, Actinobacteria
↑Firmicutes
[18]
Chen et al. Egg white, cow’s milk, wheat, peanut, soy bean ↓Bacteroidetes
↑Firmicutes
[19]
Fazlollahi et al. Egg ↑Lachnospiraceae, Streptococcaceae, Leuconostocaceae [20]
Dong et al. Cow’s milk ↑Lactobacillaceae
↓Bifidobacteriaceae, Ruminococcaceae
[115]
Diaz et al. Cow’s milk ↓Coriobacteriaceae [21]
Berni Carnani et al. Cow’s milk ↑Bacteroides, Alistipes [22]
Kourosh et al. Tree nuts, fish, milk, egg, sesame, soy ↑Oscillibacter valericigenes, Lachnoclostridium bolteae, 
Faecalibacterium sp.
[23]
Table 2 Production of the short-chain fatty acids by the gut microbiota
Short-chain 
fatty acids
Pathway Microbiota References
Acetate Acetyl-CoA Most enteric bacteria [31]
Wood–Ljungdahl pathway Blautia hydrogenotrophica
Propionate Succinate pathway Negativicutes, Bacteroidetes [32]
Acrylate pathway Megasphaera elsdenii, Clostridium propionicum
Propanodiol pathway Salmonella enterica, Roseburia inulinivorans, Ruminococcus obeum
Butyrate Butyrate kinase and phosphotransbutyrylase Coprococcus species [31]
Butyryl-coenzyme A (CoA):acetate CoA-transferase Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, 
Eubacterium hallii Anaerostipes spp.
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in turn promoting the tolerogenic CD103+ DC func-
tion and protecting against food allergies [35]. Moreover, 
short-chain fatty acids can reduce the production of pro-
inflammatory cytokines including IL-1β, IL-6, IL-17 [36], 
and meanwhile increase the production of anti-inflam-
matory mediators including IL-10 [36, 37]. Thus, short-
chain fatty acids are viewed as a key factor in promoting 
immunological tolerance towards harmless antigen and 
preventing inflammation.
Adaptive immunity
Adaptive immune responses are divided into two types: 
humoral immunity, regulated by B cells [38, 39], and 
cell-mediated immunity, regulated by T cells. The role 
of Tregs, subset of CD4+ T cells in oral tolerance devel-
opment to food allergen, have been confirmed in animal 
models [40, 41] as well as human studies [42, 43] in which 
the induction of allergen-specific Treg cells is highly 
associated with a favourable allergy outcome. Microbiota, 
especially Clostridia species, in this case, were shown to 
be able to induce the production of Tregs [44, 45], which 
helps to inhibit allergic inflammation and promote oral 
tolerance [12, 46–48].
Specific Taxa related to food allergy across multiple 
studies
Bacteroidetes and Firmicutes comprise 90% of the micro-
biota population [49] and the colonization of these two 
microbiota phyla is associated with the pathogenesis of 
food allergy [50], as summarized in Table 3.
Bacteroidetes
An association between Bacteroidetes phyla in the gut 
and food allergy was found in a few epidemiologic stud-
ies [15, 18, 19]. Using gene sequencing methods, these 
studies identified that children with various types of food 
allergy had a lower relative abundance of Bacteroidetes 
compared with healthy children. The exact role of Bac-
teroidetes is unclear. However, a murine study indicated 
that Bacteroides fragilis, a species of Bacteroidetes, was 
able to produce polysaccharide A (PSA), which increased 
the suppressive capacity of the Treg cells and increased 
the production of IL-10 from Foxp3+ T cells [51]. 
The accumulated IL-10 mediates tolerance at mucosal 
surfaces and prevents intestinal inflammation. Further 
clinical studies in humans are needed to examine the reg-
ulatory role of Bacteroidetes in the development of food 
allergy.
Firmicutes
Firmicutes is the largest microbiota phylum contain-
ing more than 200 genera [52]. Most of the Firmicutes 
detected in the gut belong to the Clostridium clusters 
XIVa and IV. Both groups comprise members of the gen-
era Clostridium, Eubacterium and Ruminococcus. Fir-
micutes are the most important butyrate producer in the 
gut and help to reduce inflammation through the inhi-
bition of histone deacetylase [30]. A number of studies 
using 16S rRNA gene sequencing have identified a lower 
relative abundance of bacterial class Clostridia (bacte-
rial phylum Firmicutes) in children with food allergy 
compared to healthy children [12, 13, 53, 54]. It is an 
accepted scientific knowledge that Clostridia promotes 
the accumulation of Treg cells [44, 45, 47, 55]. However, 
a study conducted by Stefka st al [55] demonstrated that 
Clostridia elevated IL-22 expression by RAR-related 
orphan receptor gamma (RORγt)+ ILCs and T cells, 
which in turn increasing an early, innate, barrier protec-
tive response. At the same time, Clostridia also elevated 
the production of IL-17, which in turn reducing intestinal 
epithelial permeability. Contradictory results also exist 
that patients with food allergy showed an increase in lev-
els of Clostridia [18, 19, 56]. The genera of Clostridia that 
have been identified so far to have an association with 
food allergy are Clostridium [13, 18, 19, 53] and Rumino-
coccus [13, 15, 19, 54]. Diesner et al. reported that mice 
tolerant to food allergy have higher abundances of Rumi-
nococcaceae [54] compared with intolerant counterparts, 
supporting the potential protective effects of Ruminococ-
cus on food allergy. Nevertheless some discordant results 
the Clostridia class is that more clearly involved in mech-
anism of food tolerance induction and in food allergy 
protection.
Early-life colonization and environmental factors
Some studies argue that the gut microbiota is critical 
in early life for the development of the immune system 
as well as the development of allergic diseases [15, 18, 
Table 3 Gut microbiota taxa and alterations associated with food allergy
Phylum Class Genus Species Action in the Gut References
Bacteroidetes Bacteroidetes Bacteroidetes Bacteroides fragilis Increase the suppressive capacity of Tregs and 
induce the production of IL-10 from Foxp3+ T cells
[51]
Firmicutes Clostridia Clostridium
Lactobacillus
Ruminococcus
Promote the accumulation of Tregs [116]
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19, 53, 57]. The gut microbiota is unstable in the first 
2–3 years of life during the initial colonization and devel-
opment of the gut. Disruptions of microbial colonization 
during this period have been shown to increase the dis-
ease susceptibility during life. After the age of three the 
gut microbiota progresses towards an adult-like configu-
ration and it essentially remains stable unless perturbed 
[1, 5, 53].
The dramatic rise of food allergy in modern society has 
led to the postulation of the hygiene hypothesis [58]. The 
hygiene hypothesis proposes that a lack of early child-
hood exposure to infectious agents suppresses the devel-
opment of the immune system which leads to the rise of 
atopic diseases. Recent work has revisited the hygiene 
hypothesis model to include mode of delivery, antibiotic 
intake, diet [59] and synthetic chemicals as factors in 
altering gut microbiota (Fig. 1).
Mode of delivery
Perturbation of gut microbiota may influence susceptibil-
ity to food allergy [60]. It is evidenced that infants born 
vaginally are exposed to both maternal fecal and vaginal 
microbiota while infants born by caesarean section are 
exposed to maternal skin and environmental microbes 
only [50]. For instance, infants born by caesarean section 
are more likely to have lower abundance of Bacteroides 
and higher abundance of Firmicutes. Both Bacteroides 
and Firmicutes were revealed to associate with devel-
opment of food allergy [50]. A population based birth 
cohort study revealed that children born by caesarean 
section had a threefold higher chance of developing food 
allergy [61]. However, the role of the delivery mode in 
influencing the food allergy outcome remains unclear as 
the delivery mode only exhibits an effect on the immune 
system for the first 90 days [62].
Antibiotic intake
Mothers undergoing a caesarean section are more likely 
to receive antibiotics [62], which can perturb the compo-
sition of the gut microbiota and modify the risk for aller-
gic outcomes [63].
A number of studies have attempted to elucidate how 
antibiotics modify the composition of the gut microbiota 
and lead to the pathogenies of food allergy [64–66]. These 
studies revealed that antibiotic administration altered 
and reduced the microbiota diversity. A study suggested 
that antibiotic administration may cause reconstitution 
of the flora, thereby resulting in failure of the signal trans-
mission via Toll-like receptor 4 (TLR4) [64]. The inability 
to signal via TLR4 resulted in markedly increased pea-
nut-specific IgE and Th2 cytokine responses, contribut-
ing to allergic responses. Nevertheless, the association of 
antibiotic intake in early life and the development of food 
allergy is debated [67]. In a Chicago Family Cohort Food 
Allergy study, 1359 families were recruited and structure 
questionnaires were administered. This study did not find 
any association between antibiotic intake in the first year 
of life and the diagnosis of food allergy [67].
Fig. 1 Early-life colonization and environmental factors. The gut microbiota is unstable in the first 2–3 years of life during the initial colonization 
and development of the gut. During this period, the gut microbiota is vulnerable to some disruptions such as mode of delivery, antibiotic intake, 
diet and synthetic chemicals, which may increase specific IgE, induce pro-inflammatory cytokines, reduce anti-inflammatory cytokines, inhibit the 
accumulation of Treg cells, and suppress the tolerogenic CD103+ DC (dendritic cell) functions, contributing to the pathogenesis of food allergy. 
After the age of 3 the gut microbiota progresses towards an adult-like configuration and this remains the same throughout the life
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Diet
Diet plays an important role in the establishment of the 
gut microbiota and affects allergic symptoms [68, 69]. 
The dietary intake of infants starts with milk, either 
breast milk or formula [70]. Breast milk contains human 
milk oligosaccharides which stimulate the growth of Bifi-
dobacterium bifidum [71] and genus Lactobacillus [72], 
which are the main probiotic organisms in the gut, form-
ing an acidic environment with enriched short-chain 
fatty acids [73]. Consequently, breastfed infants are colo-
nized with Bifidobacteria and Lactobacilli compared with 
formula fed infants [74]. Additionally, the breastfeed-
ing duration also has an influence on the development 
of food allergy as infants with a very brief breastfeed-
ing duration have a higher risk of developing cow’s milk 
allergy [75].
The milk intake is gradually replaced by a solid food 
diet that is similar to that of the adult and composed of a 
wide-variety of dietary macronutrients such as proteins, 
fats, carbohydrates and fibres [76]. These macronutrients 
are fundamental in determining microbiota composition 
and its effect on health outcomes.
After the introduction of complementary diet, the gut 
of infants exhibit more Lactobacillus, Ruminococcus, 
Bacteroides, Peptostreptococcus and Clostridium, which 
are tryptophan-catabolizing species [77]. Tryptophan 
is an amino acid commonly presented in high protein 
food, which is required for protein biosynthesis. Tryp-
tophan metabolism plays a fundamental role in regulat-
ing the immune response as well as T cell proliferation. 
Other than this, tryptophan metabolism also induces 
IL-10 receptor-1 (IL-10R1) expression, which is essential 
in determining whether cells respond to IL-10, a potent 
anti-inflammatory cytokine that inhibits the release of 
pro-inflammatory cytokines [78].
Other than protein, fibre can also affect microbiota 
composition. The microbiota composition of the human 
gut associated with a high fibre diet is different from 
that seen with a high fat diet [79]. The gut microbiota 
with a high fat diet consisting of animal-based foods 
has higher abundance of Alistipes, Bilophila and Bacte-
roides and lower abundance of Roseburia, Eubacterium 
and Ruminococcus at genus level when compared to the 
gut microbiota with a high fibre diet [79]. The microbial 
conversions of dietary fibre to monosaccharides involve 
a number of metabolic pathways catalysed by the enzy-
matic activities of the gut microbiota and short-chain 
fatty acids are the major end-products of these micro-
bial conversions [29, 30]. Mice studies were conducted 
in order to investigate the role of dietary fibre in sup-
pressing immune response to food antigens [35, 80]. In 
these studies, mice were sensitized with food antigen and 
fed with either high fibre diet or no fibre diet. After few 
weeks of exclusion diet, mice receiving high fibre diet, 
showed significantly reduced symptoms of food allergy. 
Therefore, the “Western” diet with its high fat but low 
fibre content is proposed to be one of the reasons for the 
high prevalence of food allergy in Western countries [35, 
81].
Synthetic chemicals
Synthetic chemicals play a role in perturbing the com-
position of gut microbiota as microbial metabolism of 
chemicals by gut microbiota may cause microbial dys-
biosis [82], which in turn triggers allergy reaction [83, 
84]. For example, food additives, one of the synthetic 
chemicals, are commonly found and used in our food 
as antioxidants, colourings, and flavourings, sweeten-
ers and preservatives [83]. Mouse studies have indicated 
that such chemicals are associated with increased risks 
for food allergy [83, 84]. Food additives inhibited the 
accumulation of Treg cells, which is necessary for acqui-
sition of oral tolerance [83]. The food additives also pro-
moted the induction of allergic CD11b+ DCs, reduced 
the accumulation of tolerogenic CD103+ DCs as well as 
inhibited the induction of CD4+CD25hiT cells. Further 
to this, this study also suggested that intake of multiple 
food additives could increase the risk of developing food 
allergy.
Other synthetic chemicals, such as air pollutants, can 
be responsible for increasing the appearance of food 
allergy. Higher ambient levels of air pollutants, especially 
nitrogen dioxide have been consistently demonstrated to 
be associated with the increasing risk of allergies, includ-
ing food allergies [85–87]. The mechanism of how air 
pollutant can cause food allergy remains unknown but 
studies suggested that inhaled air pollutants were able 
to directly or indirectly modify the composition of gut 
microbiota [88], which may cause an increase in the gut 
permeability and inflammation. Furthermore, inhaled 
air pollutants can lead to a substantial inflammatory 
response via reactive oxygen species (ROS) production 
and nuclear factor kappa B (NF-κB) activation in GI tract.
Therapeutic strategies
Human [12, 15, 18, 19, 53] and murine [54] models have 
demonstrated that study subjects with food allergy have 
distinct gut signatures and a different gut microbiota 
composition. Moreover, there is growing evidence that 
alteration of the gut microbiota may explain the devel-
opment of food allergy [40, 41]. Microbial colonization 
has been shown to promote the induction of Treg cells, 
which is necessary to modulate the immune system and 
maintain tolerance to self-antigens [40, 41]. Microbiota 
may also influence the epigenetic modification of genes. 
It has been demonstrated that various forms of epigenetic 
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changes, such as DNA methylation and histone modifica-
tion, regulate the immune system. Also microbial derived 
metabolites, such as short-chain fatty acids, have been 
shown to reduce pro-inflammatory cytokines and induce 
anti-inflammatory mediators as well as inhibit histone 
deacetylases [36].
Research indicates that environmental factors affect 
the microbiota composition making it an ideal target of 
research to find new interventions to desensitize food 
allergy.
Probiotic supplementation
The use of probiotic supplementation seems an attrac-
tive option for the prevention and treatment of allergic 
diseases. Probiotics are defined as “live microorganisms 
which, when administered in adequate amounts as part 
of food, confer a health benefit on the host” [89, 90]. Pro-
biotics can act as promoters of an adequate balance in 
the gut microbiota to prevent the development of aller-
gies. The beneficial effects of probiotics involve restoring 
intestinal permeability to normal, improving the intes-
tine’s immunological barrier function (both physical and 
mucous layer), promoting IgA production and inhibiting 
the release of proinflammatory cytokines through regu-
lating gut microbiota composition [91, 92].
A well-characterised bacterial probiotic in desensitiz-
ing food allergy, especially cow’s milk allergy, is Lacto-
bacillus rhamnosus GG [93]. Dietary intervention with 
Lactobacillus rhamnosus GG was found to reduce aller-
gic responses towards cow’s milk in murine [94, 95] and 
human studies [93, 96, 97]. Lactobacillus rhamnosus GG 
was able to increase the production of different cytokines 
with proinflammatory (TNF-α and IL-6) or regulatory 
(IL-10) functions [98]. In addition, Lactobacillus rham-
nosus GG also induced the accumulation of colonic 
Treg cells in the intestine [99]. In addition, Lactobacillus 
rhamnosus GG was able to increase FoxP3 demethyla-
tion rate, increase IL-4 and IL-5 DNA methylation rate, 
reduce IL-10 and IFN-γ DNA methylation rate, increase 
the expression of miR-155, -146a, -128 and -193a, to pro-
mote the acquisition of cow’s milk tolerance 12  months 
after treated with extensively hydrolyzed casein formula 
containing the probiotic Lactobacillus rhamnosus GG 
[97].
One study found that Lactobacillus rhamnosus GG 
showed a weak effect in desensitizing peanut allergy 
[100]. Most of the participants who received this probi-
otic and peanut oral immunotherapy passed the oral food 
challenge after receiving the treatment for 18  months 
and still passed the oral food challenge after 2 to 5 weeks 
after that. Moreover, participants who received probiotic 
and peanut oral immunotherapy showed a decrease in 
peanut sIgE levels and skin prick test wheal size, as well 
as an increase in peanut sIgG4 levels, at the end of treat-
ment. Three months after treatment ended, these partici-
pants still had low sIgE levels and a small skin prick test 
wheal size. However, there was no convincing evidence 
that probiotic was effective in reducing allergic reactions 
to food as this study only compared between partici-
pants who received probiotic and peanut oral immuno-
therapy and participants who received placebo without 
including oral immunotherapy group only and probiotic 
group only. Also the prolonged tolerance towards peanut 
remains unclear as the participants in this study were not 
followed up beyond 3 months.
A mouse model of shellfish allergy demonstrated that 
oral administration of the probiotic strain Bifidobacte-
rium longum reduced the specific IgE and stimulated 
dendritic cell maturation and CD103+ tolerogenic DCs 
accumulation in gut-associated lymphoid tissue. This, in 
turn, increased Tregs differentiation and suppressed Th2 
responses [95, 101]. A murine study of cow’s milk allergy 
showed that oral administration of Bifidobacterium 
longum subsp. Infantis LA308 strain induced the expres-
sion of IL-10 and skewed the immune response to Th1. 
These results are encouraging to find a candidate probi-
otic strain to perform a clinical trial.
Two other murine studies have reported the capac-
ity of Clostridium butyricum to reduce adverse reac-
tions to egg and cow’s milk [46, 102]. The mechanism 
of how Clostridium butyricum is able to inhibit allergic 
inflammation remains unknown. Shi [102] suggested 
that the therapeutic effect of Clostridium butyricum may 
be generated by IL-10, as the IL-10-producing antigen 
specific Breg was found in mice with egg allergy which 
were administered with specific immunotherapy and 
Clostridium butyricum. On the other hand Zhang [46] 
suggested that Clostridium butyricum increased sIgA, 
CD4+CD25+Foxp3 Treg cell as well as reversed the 
imbalance of Th1/Th2 and Th17/Treg. These interesting 
results require further validation from human clinical 
trials.
There are three limitations on probiotic dietary inter-
vention. First, the effect of probiotic is strain specific 
[103] and may vary depending on the individual’s life-
style and baseline gut microbiota profile [104]. Secondly, 
abrupt termination of probiotic dietary intervention may 
further increase the gut dysbiosis [105]. Lastly, there are 
only a few studies about probiotic dietary intervention 
and further studies are needed to validate the findings in 
human system.
Prebiotic supplementation
Prebiotic is defined as “nonviable food component that 
confers a health benefit on the host through modulation 
of the gut microbiota” [106]. An animal study reported 
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that cocoa, a source of antioxidant polyphenols, may be 
used to desensitize oral allergy [107]. In this study, rats 
administered with a 10% cocoa diet achieved oral toler-
ance and had a lower relative abundance of bacterial phy-
lum Firmicutes and Proteobacteria and a higher relative 
abundance of Tenericutes and Cyanobacteria spp. com-
pared to rats who received a standard diet, either orally 
sensitized or non-sensitized rats. It was suggested that 
the cocoa diet was able to increase the proportion of 
TCRγδ+ and CD103+CD8+ cells and decrease the pro-
portion of CD62L+CD4+ and CD62L+CD8+ cells in 
mesenteric lymph nodes [108], regulate Treg cells func-
tion and reduce IgA production [107] through modula-
tion of gut microbiota. This suggests that a cocoa diet has 
potential in regulating allergic immune responses in the 
human body and is of interest to investigate further.
Synbiotic supplementation
Synbiotics refers to a mixture of probiotics and prebiot-
ics, designed to improve the survival of the beneficial 
microbiota as well as stimulate the growth of beneficial 
microbiota in the gastrointestinal tract [106].
A pioneer study tested a prebiotic blend of fructo-oli-
gosaccharides with the probiotic strain Bifidobacterium 
breve M-16V. Infants with suspected non-IGE cow’s milk 
allergy were administered with a hypoallergenic, nutri-
tionally complete amino-acid based formula either with 
or without the synbiotics [109]. The relative abundance 
of Bifidobacteria was increased in infants with cow’s milk 
allergy who were administered synbiotics. Moreover, the 
microbiota profile of these allergic infants became simi-
lar to that of healthy breastfed infants. More studies are 
required to confirm this therapeutic effect of synbiot-
ics supplementation in desensitizing food allergy. It is 
a promising therapeutic strategy for improving the gut 
ecosystem and reducing food allergy responses.
Fecal microbiota transplantation
Fecal microbiota transplantation is a possible therapeutic 
for food allergy. Transplantation of fecal bacteria from a 
healthy donor to a disease recipient can re-establish gut 
microbiota diversity leading to the resolution of symp-
toms [110, 111]. As dysbiosis affects the development of 
food allergy [12], restoration of immune homeostasis and 
reconstruction of the impaired gut microbiota barrier 
by fecal microbiota transplantation may be able to pro-
mote the development of oral tolerance [110]. Recently, 
a human study has revealed that fecal microbiota trans-
plantation is able to induce remission of infantile allergic 
colitis through restoration of gut microbiota diversity 
[112]. Although the available data in this field remain lim-
ited and the relevant scientific work has only just begun, 
this recent success in reducing infantile allergy colitis 
symptoms suggests that fecal microbiota transplantation 
can be a feasible strategy to arrest food allergy responses.
Synthetic stool substitute
Considering the strain specific effect of probiotic [103] 
and limited patient acceptance of fecal microbiota 
transplantation [113], a synthetic stool substitute was 
proposed in a pilot study [113]. In this study, a stool sub-
stitute with 33 strains was developed based on the fecal 
microbiota diversity of a healthy donor, also known as 
RePOOPulate. Clostridium difficile infection symptoms 
of patients were eradicated after 2–3  days of RePOOP-
ulate treatment and this symptom free state lasted for 
6  months. This synthetic stool substitute is so far only 
tested on two patients with Clostridium difficile infec-
tion, yet its potential benefit of reverting normal bowel 
pattern and restoring immune homeostasis may help to 
reduce allergic reactions towards food.
Microbiome-based therapy
Microbiome-based therapy can be viewed as a potential 
way in treating food allergy. In a mouse study, germ free 
mice were colonized with human feces from infants with 
cow’s milk allergy and age and gender matched healthy 
infants [114]. Healthy-colonized mice had a higher abun-
dance of Anaerostipes caccae when compared with cow’s 
milk allergy colonized mice. Mice were then adminis-
tered with Anaerostipes caccae in order to further investi-
gate the role of Anaerostipes caccae in regulation of gene 
expression. Anaerostipes caccae were able to reduce the 
expression of Th2 dependent, antibody (serum BLG-spe-
cific IgE and IgG1), Acot12 expression as well as cytokine 
responses IL-13 and IL-4, which promoted oral tolerance 
towards cow’s milk allergy. This opens up a new perspec-
tive of food allergy therapy on human.
Conclusion
Studies have shown that the gut microbiota composition 
is vulnerable to disruptions in early life and that associ-
ated changes in host-microbiota homeostasis can cause 
food allergy. These studies support a regulatory role of 
the gut microbiota in the manifestation of food allergy, 
particularly in early life, but many questions remain and 
the underlying mechanisms are yet to be defined. The 
majority of our knowledge stems from animal studies and 
more human studies are required to validate the precise 
role of the gut microbiota in the development of food 
allergy. Evidence is emerging to suggest that therapeutic 
strategies in modifying gut microbiota composition are 
useful in the prevention, management and treatment of 
food allergy. Such strategies are apparent future research 
directions for developing prophylactic and therapeutic 
approaches against food allergy.
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